A Phase 2, Randomized, Double-Blind, does-finding, Parallel Group, Multi-Center Study to evaluate Efficacy and Safety of M118103 in Subjects with Prurigo nodularis.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210028

Enrollment

120

Registered

2021-04-09

Start date

2021-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prurigo nodularis

Interventions

Patients apply investigatuional drug to evaluation site twice a day (in the morning and night).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Prurigo nodularis patients.

Exclusion criteria

Exclusion criteria: Patients who have skin symptoms that could effect on evaluation of effectiveness of investigational drug.

Design outcomes

Primary

Measure	Time frame
The ratio of patients whose thickness of evaluational nodule is decreased over 50 % .	—

Contacts

Public ContactClinical Trials Infomation

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026